Interleukin 2 therapy in infectious diseases: rationale and prospects. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Interleukin 2 therapy in infectious diseases: rationale and prospects.

Infection. 1984 Jul-Aug;12(4):298-302. Unique Identifier : AIDSLINE MED/85029409
Siegel JP; Rook AH; Djeu JY; Quinnan GV Jr

Abstract: Clinical trials using interleukin 2 as a therapeutic immunomodulating agent in patients with acquired immunodeficiency syndrome have recently begun. In this article we present data from studies which indicate the ability of interleukin 2 in vitro to augment clinically important cytotoxic immune responses in lymphocytes from these patients. These studies provide both a rationale for the current trials and a model for evaluating the potential for use of interleukin 2 in other infectious diseases. We outline the types of infectious diseases in which interleukin 2 may prove to be useful and the therapeutic strategies in which it may play a role.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Cells, Cultured Clinical Trials Cytomegalovirus Infections/IMMUNOLOGY/*THERAPY Cytotoxicity Tests, Immunologic Cytotoxicity, Immunologic Homosexuality Human Immunotherapy *Interleukin-2/IMMUNOLOGY Killer Cells, Natural/IMMUNOLOGY Lymphatic Diseases/IMMUNOLOGY/*THERAPY Male CLINICAL TRIAL JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/immunology/KWDtherapycells,culturedclinicaltrialscytomegalovirusinfections/immunology/KWDtherapycytotoxicitytests,immunologiccytotoxicity,immunologichomosexualityhumanimmunotherapyKWDinterleukin-2/immunologykillercells,natural/immunologylymphaticdiseases/immunology/KWDtherapymaleclinicaltrialjournalarticle
850228
M8520051

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .